Just before the New Year, the US Food and Drug Administration (FDA) awarded national priority vouchers for two investigational drugs for their “potential to increase access through affordability for American patients.”
The products are Merck’s enlicitide decanoate, an oral PCSK9 inhibitor for lowering LDL cholesterol, and Sacituzumab tirumotecan, an antibody-drug
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day